Tumor cells expressing the thymidine kinase gene of the herpes simplex virus ( HSV -tk ) are rendered highly susceptible to the cytotoxic effects of different antiherpes drugs. In an attempt to enhance cytotoxicity of this therapeutic approach in glioma and other tumor cell lines transduced with the HSV -tk gene, we evaluated tumor cell killing following co -administration of two different prodrugs metabolized by HSV -tk, ( E ) -5 -( 2 -bromovinyl ) -2 H -deoxyuridine ( BVDU ), and ganciclovir ( GCV ). In 8 of 12 cell lines investigated, addition of BVDU in concentrations showing no cytotoxic effect or only limited cytotoxicity could enhance GCVmediated cell killing by as much as one order of magnitude. In co -cultures consisting of HSV -tk + ( 9L STK ) and HSV -tk À ( 9L wildtype ) cells, we also observed potentiation of GCV -mediated cytotoxicity in the presence of BVDU, suggesting strongly enhanced bystander cell killing. BVDU is thought to exert its cytotoxic effect through inhibition of thymidylate synthase activity or by incorporation into replicating DNA. Both effects could be observed in all HSV -tk ± expressing cells investigated, including cell lines which did not exhibit cytotoxicity after incubation with BVDU. These findings argue against current concepts of BVDU -mediated cytotoxicity in HSV -tk ± expressing cells. Taken together, our data suggest that gene therapy utilizing prodrug activating enzymes may be rendered more effective by simultaneous treatment with two different prodrugs metabolized by the same enzyme. Cancer Gene Therapy ( 2001 ) 8, 388 ± 396
S everal nucleotide analogs are phosphorylated by the thymidine kinases from different herpes viruses and this results in the highly selective inhibition of viral replication. 1 Whereas the cytotoxic effects of these drugs on mammalian cells lacking viral thymidine kinase activity are almost negligible, it has been observed previously that ( tumor ) cell lines expressing herpes simplex virus thymidine kinase ( HSV-tk ) are highly susceptible to acyclovir ( ACV ) and ( E )-5 -( 2-bromovinyl )-2 H -deoxyuridine (BVDU ). 2 ± 4 This has led to innovative efforts to develop a more selective and more effective cancer treatment, namely``enzyme/ prodrug gene therapy''. 5 ± 7 In later studies, ganciclovir (GCV ) was demonstrated to be superior to ACV and since that time has been the prodrug of choice for multiple clinical HSV-tk ± based gene therapy trials for the treatment of several different tumors including malignant gliomas. 8, 9 The mechanisms through which ACVand GCV induce cell death in HSV-tk ± expressing cells most likely include chain termination after incorporation of GCV triphosphate into replicating DNA as well as inhibition of DNA polymerase alpha. 10 ± 12 These changes subsequently result in the induction of apoptosis in HSV-tk ± expressing cells and adjacent`b ystander cells'' not expressing the HSV-tk gene. 13 ± 16 Similar to what has been observed with GCV or ACV, the antiviral activity of BVDU has been associated with preferential inhibition of viral DNA synthesis over cellular DNA synthesis due to selective inhibition of HSV DNA polymerase. 17 BVDU is currently evaluated in clinical trials for the treatment of herpes virus infections. 18 ± 21 In contrast to GCV and ACV, the cytotoxic effect of BVDU on HSV-tk ± expressing cells has been primarily attributed to inhibition of thymidylate synthase (TS ) activity. 12, 22 Therefore, BVDU appears to act in a manner similar to other 5-(halogensubstituted )-antimetabolites including 5 -fluorouracil, a widely used antitumor agent. However, BVDU requires prior phosphorylation by HSV-tk accounting for its highly selective cytotoxic effects on HSV-tk ±expressing cells. 23, 24 Nevertheless, in a more recent study in which different prodrugs, including BVDU, were examined for their cytotoxic effects on varicella zoster virus thymidine kinase ±expressing cells, the role of TS has been discussed controversially.
Data available from several clinical trials utilizing the HSV-tk /GCV gene therapy strategy suggest that this form of gene therapy requires improvements for further clinical use. 9 Such attempts may include the development of new vector systems resulting in higher transduction efficiencies and higher levels of transgene expression as well as strategies to enhance the bystander effect and accompanying immune reactions.
A novel approach rendering enzyme /prodrug gene therapy more effective may involve co -administration of two different prodrugs serving as substrates for the same enzyme. For this purpose, we investigated whether cytotoxicity in HSV-tk ± expressing cells and bystander cells could be enhanced by concomitant treatment with two different prodrugs, GCV and BVDU.
MATERIALS AND METHODS

Cell lines
PA317 cells 26 (which are derived from NIH3T3 cells) and C6 rat glioma cells were obtained from the American Type Culture Collection (Rockville, MD ). Human tumor cell lines and the rat gliosarcoma cell line 9L were either obtained from the Tumor Cell Bank of the Brain Tumor Research Center, University of California, San Francisco, or from American Type Culture Collection. PA317 cells, which are commonly used for the production of amphotropic retroviruses, express the HSV-tk gene, 26 rendering them susceptible to the cytotoxic effects of GCV. Additional HSV-tk ± expressing cell lines were generated after transfection with the STK retrovirus carrying the HSV-tk and neomycin phosphotransferase genes. 6 For that purpose, C6 and 9L cells were transduced with supernatant from É2-STK cells containing ecotropic STK retroviruses in the presence of polybrene using a standard procedure. 27 Ecotropic STK retroviruses from É2-STK cells were used for the transduction of PA317 cells, a cell line that supports the generation of amphotropic retroviruses. Supernatant from these cells containing amphotropic STK retroviruses was then used for retroviral transduction of human tumor cell lines. 27 Pools of HSV-tk ±expressing cells were generated by G418 selection and tested for GCV sensitivity. Cells were cultured as described previously.
16,28
Cytotoxicity assays
In 96 -well plates, 10,000 cells / well were seeded and treated with different concentrations of GCV and/ or BVDU. After 5 days, the number of surviving cells per well was obtained by cell counts in Neubauer chambers, excluding dead cells staining with trypan blue. The fraction of surviving cells was determined by dividing the number of surviving cells after treatment by the number of cells in untreated wells. In preliminary experiments, cytotoxicity was also assessed by crystal violet staining of monolayers. For this purpose, cell monolayers were carefully rinsed with phosphate -buffered saline, fixed and stained with 0.4% crystal violet in 20% methanol for 15 minutes, and finally rinsed thoroughly with tap water. Cytotoxicity was also measured by an enzymatic assay, which was performed as recommended by the manufacturer ( MTS assay; Promega, Madison, WI ).
Determination of TS activity
TS activity was quantified by adaptation of a previously published method, which is based on the release of free tritium after deamination and further reductive methylation of 5 -[ 3 H ]dCyd by TS. 29 This metabolization is independent of thymidine kinase activity. For this, 2Â10 5 cells /well were seeded in 24 -well plates. After 1 day, cells were pretreated with different concentrations of BVDU. We used preincubation periods of 6 hours because this time period proved to be sufficient for high -enough doses of BVDU to completely inhibit TS activity without evidence of cytotoxic effects ( data not shown ). After preincubation over 6 hours, cells were incubated with 3 Ci /mL 5-[
3 H ]dCyd/ well (obtained from Amersham -Buchler, Braunschweig, Germany, at 1 mCi / mL ) in 300 L medium containing BVDU in the same concentrations as in the preincubation step. After 60 minutes, 100 L of cell supernatant was added to 300 L of 15% activated charcoal in 5% trichloro -acetic acid (48C ) and samples were vortexed. After centrifugation in a microcentrifuge at maximum speed for 5 minutes, 200 L of the supernatant containing free tritium was added to 10 mL of scintillation fluid and samples were counted in a scintillation counter. Fresh 5 -[
3 H ]dCyd ±containing medium was processed in the same way, and the results were corrected for the background levels recorded for these controls. HSV -tk ± expressing cell lines were treated with different concentrations of GCV and / or BVDU. After 5 days, cytotoxicity was determined by crystal violet staining of cell monolayers as described in Materials and Methods. The cytotoxic effects were confirmed by independent experiments in which cytotoxicity was assessed with the MTS assay. + , BVDU enhanced GCV -mediated cytotoxicity; À , BVDU did not enhance cytotoxicity of GCV. Figure 4 , respectively. After 12 hours, the medium containing radioactive substitutes was aspirated off, cells were washed with phosphate -buffered saline, and fixed with 200 L methanol:acetic acid (vol /vol, 3:1 ) at room temperature for 10 minutes. Ice -cold 10% TCA was added and thereafter, cells were washed several times with 5% TCA on ice. The precipitates were solubilized with 200 L 1 M NaOH at 658C for 1 hour, neutralized with 200 L 1 M HCl, and counted in a scintillation counter after scintillation fluid had been added. Counts per minute were calculated into picomoles per 20,000 cells.
RESULTS
BVDU enhances GCV -mediated cytotoxicity in HSV -tk ± expressing cells
In a panel of HSV-tk ± expressing rodent and human cell lines, different combinations of GCV and BVDU were evaluated for their cytotoxic effects. In initial screening experiments, cytotoxicity was semiquantitatively assessed by fixation and staining of cell monolayers with crystal violet. BVDU enhanced the cytotoxic effects of GCV in 9 of 13 HSV-tk ±expressing cell lines tested (Table 1 ) . These effects were confirmed by means of an established enzymatic assay (MTS assay; data not shown ). To quantify as to what extent cytotoxicity could be enhanced, actual cell numbers were obtained after incubation with different concentrations of GCV and /or BVDU (Fig 1) . For example, in 9L STK cells, 200 nM BVDU did not lead to significant cell death when administered alone, but strongly augmented the cytotoxic effect of 0.5 M GCV. Instead of 20% cell survival observed after treatment with 0.5 M GCV alone, addition of 200 nM BVDU resulted in less than 1% surviving cells. Likewise, in a panel of HSV-tk ± expressing cell lines, including several human glioma cell lines, concentrations of BVDU showing no or only limited cytotoxicity potentiated the cytotoxic effect of GCV by up to (and sometimes more than ) one order of magnitude ( Fig 1 ) . In cells which do not express HSV-tk co -treatment Figure 1 . Cytotoxicity of combinations of GCV and BVDU on HSV -tk ± expressing cell lines. HSV -tk ± expressing cell lines were incubated with different concentrations of GCV and / or BVDU as indicated on the x axis ( M GCV / nM BVDU ). After 5 days, the fraction of surviving cells was determined ( y axis ) by counting cells, excluding nonviable cells staining with trypan blue. The bars represent standard deviations. Each cell line was analyzed for statistically significant differences between different treatment groups by ANOVA followed by Student -Newman -Keuls test. In all cell lines shown, cytotoxicity determined after co -treatment with GCV and BVDU in the concentrations indicated differed significantly from cytotoxicity observed after single treatment with GCV or BVDU in respective concentrations ( *P < .05 ). Significant differences between other treatment groups have not been indicated.
Cancer Gene Therapy, Vol 8, No 5, 2001 with > 20 M GCV and > 1000 nM BVDU, did not result in detectable cytotoxicity (data not shown). In contrast to those cell lines depicted in Figure 1 , several HSV-tk ± expressing cell lines were not affected by BVDU when examined for GCV-mediated cytotoxicity ( Table 1) . These included a rat glioma cell line ( C6 STK ), two human colorectal carcinoma cell lines ( WiDr STK and HCT116 STK ), and a human glioma cell line (U343 STK ). In these cell lines, there was little or no evidence of cytotoxicity after incubation with BVDU in concentrations that were highly cytotoxic to most other HSV-tk ± positive cell lines, suggesting inherent resistance to this drug. For example, in WiDr STK cells, incubation with 5000 nM BVDU did not result in measurable inhibition of cell proliferation ( data not shown).
BVDU enhances GCV -mediated cytotoxicity in HSV -tk
À bystander cells
There is ample evidence that the bystander effect is mediated by gap junctional intercellular communication. 28,30 ± 33 Because nucleotides and their analogs can be exchanged readily between neighboring cells through gap junctions, both phosphorylated GCV and BVDU may be transferred onto HSV-tk À cells and lead to enhanced cytotoxicity. This was investigated by treating co -cultures of 9LSTK and 9L cells plated at different ratios with the indicated concentrations of GCV and/or BVDU (Fig 2A and B ) . Figure 2A illustrates that BVDU enhances the GCV-mediated bystander effect on HSV-tk À 9L cells. This effect is diminished with an increasing fraction of bystander cells. Figure 2B shows that in co -cultures of 9LSTK /9L cells ( ratio 1:2 ), addition of 200 or 500 nM BVDU enhanced the cytotoxic effects of 2 or 0.5 M GCV, respectively, by about one order of magnitude. Compared with homogenous 9L STK cultures, in 9LSTK /9L co -cultures, a higher dose of BVDU was required to enhance the cytotoxicity of 0.5 M GCV by about one order of magnitude (500 vs. 200 nM; cf. Figures 1 and 2 ) . Addition of both drugs in the indicated concentrations leads to only 2% surviving cells from a population consisting to 66% of HSV-tk À cells. This clearly indicates that killing of HSV-tk À cells utilizing the bystander effect can be achieved much more effectively by using two different prodrugs. The combination of both drugs also resulted in higher cytotoxicity than what can be achieved with the highest dose of GCV (20 M ) tested ( Fig 2B ) , a dose lying beyond serum levels routinely achievable in patients without limiting toxicity. Taken together, these date indicate that different combinations of BVDU and GCV can also enhance cell death in co -cultures of HSV-tk + cells and HSV-tk À bystander cells.
Inhibition of TS by BVDU
Inhibition of TS activity has been suggested as the principal mechanism by which BVDU exerts its cytotoxic effects on HSV-tk ± expressing cells. 12, 22 As shown in Figure 3 , BVDU inhibited TS activity in all HSV-tk + cell lines tested in a dose -dependent manner. This effect was observed in both cell lines highly sensitive to BVDU as well as cell lines rather resistant towards the cytotoxic effects of BVDU ( Fig 3 ) . Similar and higher concentrations of BVDU did not inhibit TS activity in the parental HSV-tk À cell lines (data not shown). In addition, GCV did not inhibit TS activity ( data not shown ). At very low concentrations of BVDU (i.e., at 10 ±20 nM ), many cell lines showed stimulation of TS activity, although, at higher concentrations, TS activity was Figure 2 . Effect of GCV / BVDU combinations on the bystander effect. HSV -tk ± expressing 9L cells ( 9LSTK ) were co -cultured with HSV -tk À 9L cells serving as bystander cells with different concentrations of GCV and / or BVDU. In ( A ), cytotoxicity was determined for different ratios of HSV -tk + to HSV -tk À cells by crystal violet staining of monolayers. In ( B ), 9LSTK and 9L cells were co -cultured in a ratio of 1:2. The fraction of surviving cells relative to untreated controls was determined by trypan blue exclusion of nonviable cells. The bars represent standard deviations. Statistically significant differences between different treatment groups were analyzed by ANOVA followed by Student -Newman -Keuls test. Cytotoxicity determined after co -treatment with GCV and BVDU in two different combinations differed significantly from cytotoxicity observed after single treatment with GCV or BVDU when administered in respective concentrations ( *P < .05 ). Other significant differences between different treatment groups have not been indicated.
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completely suppressed in these cells. There is no relationship between doses of BVDU inhibiting TS activity and doses of BVDU having an effect on GCV-mediated cytotoxicity. For example, in A172STK, SF295STK, and U87STK cells, doses of BVDU between 50 and 200 nM clearly enhanced GCV-mediated cytotoxicity ( cf . Fig 1) , although similar doses only elicited weak or no inhibition of TS activity in these cell lines. Moreover, HSV-tk ± expressing cell lines not sensitive to BVDU (i.e., WiDr STK, HCT116 STK, and C6 STK ) showed complete inhibition of TS activity, with doses of BVDU not eliciting cytotoxic effects. altered. As shown in Figure 4 , the incorporation of [ 3 H ]GCV was not altered after addition of unlabeled BVDU and vice versa. Importantly, the concentrations of labeled and unlabeled GCV and BVDU chosen were in the range by which cytotoxic effects have been observed after incubation for 5 days and by which BVDU could enhance GCV toxicity. Yet, at the same time, the concentrations of [ 3 H ]BVDU employed in these experiments were limited by its specific activity.
DISCUSSION
Our in vitro data suggest that gene therapy with prodrugactivating enzymes may be rendered more effective by simultaneous treatment with two different prodrugs. In this study, we demonstrated that GCV-mediated cytotoxicity on HSV-tk ± expressing cells can be augmented by the addition of a different nucleotide analog, BVDU. However, there is variation among tumor cell lines with respect to the extent to which BVDU could enhance GCV toxicity and with respect to the actual concentrations required for this effect. Whereas in some cell lines different combinations of BVDU and GCV could enhance cytotoxicity by about one order of magnitude, other cell lines showed no or only negligible enhancement of GCV-mediated cytotoxicity after addition of BVDU, i.e., WiDr STK, HCT116 STK, C6 STK, and U343 STK. Interestingly, these cell lines only showed very limited cytopathic effects when treated with high doses of BVDU alone, suggesting that BVDU may preferentially enhance GCV-mediated cytotoxicity in cell lines that are sensitive to BVDU. As described for other cell lines, 12, 22 the very low concentrations of BVDU required for eliciting cytotoxic effects and for augmenting GCV cytotoxicity in PA317 cells can be attributed to the fact that this cell line, which is derived from NIH3T3 cells, lacks cellular thymidine kinase activity. Nevertheless, the doses of BVDU actually required to enhance GCV-mediated cell killing did not elicit relevant cytotoxic effects when administered alone. This has clearly been observed in PA317 (5 nM BVDU ) and 9L STK ( 200 nM BVDU ) cells, as well as U87 STK (200 nM BVDU ) and SF295 cells ( 50 nM BVDU ). In the latter two cell lines, the indicated BVDU doses elicited only negligible cytotoxic effects themselves. Such drug interactions have been regarded as an unambiguously and clearly defined form of``synergism'', 34 which has also been termed``potentiation''. 35 Mathematical models developed for the description of less obvious drug interactions, i.e., when both substances elicit considerable effects themselves, continue to be debated controversially and have not been employed in our study. 34 ± 36 Other strategies have been developed to improve enzyme / prodrug gene therapy based on the combination of two different prodrug -activating enzymes, i.e., HSV-tk and Escherichia coli cytosine deaminase. Interestingly, this approach involves inhibition of TS by 5 -fluorouracil ( generated from 5-fluorocytosine by E. coli cytosine deaminase ), which is thought to increase phosphorylation of GCV. 37 ± 40 In addition, another study employed HSV-tk / GCV together with different TS inhibitors, which also included BVDU resulting in synergistic cell killing. 41 We investigated two mechanisms possibly associated with BVDU -mediated cytotoxicity: (a ) incorporation of GCV and BVDU into DNA and (b ) inhibition of TS. It had been suggested that inhibition of TS activity may represent the principal mechanism of BVDU -mediated cytotoxicity on HSV-tk ± expressing cells. 12, 22 Our data, however, indicate that BVDU is a potent inhibitor of TS activity in all HSVtk ± expressing cell lines tested irrespective of their susceptibility to the cytotoxic effects of this drug. In addition, there is no relationship between the concentrations leading to TS inhibition and the concentrations required for eliciting a cytopathic effect or potentiation of GCV. At very low concentrations, BVDU may even stimulate TS activity as could be observed in several cell lines. The mechanisms underlying this effect and its relevance remain to be resolved. Taken together, our data do not support the hypothesis that inhibition of thymidylate activity necessarily results in enhanced GCV cytotoxicity.
Previously, it has been demonstrated that BVDU and a similar substance, IVDU, appear to be incorporated into DNA. 22, 42 In further studies, however, it had been discussed controversially if this is likely to be associated with BVDUmediated cytotoxicity. 22, 25 In our study, all HSV-tk ± expressing cell lines tested incorporated BVDU into DNA as determined by TCA precipitation, and it may be hypothesized that synchronous incorporation of both BVDU and GCV into DNA results in enhanced cytotoxicity. However, we observed that C6 STK cells, in which BVDU does not enhance GCV-mediated cytotoxicity, incorporated GCV and BVDU to a similar extent as responding cell lines ( i.e., PA317 and 9L STK ). This argues against DNA incorporation as a critical feature of BVDU -mediated cytotoxicity. In addition, BVDU had no effect on GCV incorporation into DNA and vice versa, which is surprising because it had been hypothesized that increased phosphorylation of GCV may occur after inhibition of TS activity. 39 Taken together, both inhibition of TS activity and incorporation of BVDU into DNA appear to represent insufficient mechanistic concepts to explain BVDU -mediated cytotoxicity and its potentiating effect on GCV cytotoxicity in HSV-tk ±expressing cells. However, should one or both mechanisms be associated with BVDUmediated cytotoxicity, one has to postulate that certain cell lines have developed resistance to these mechanisms. In addition to these mechanisms, which have been best studied with regard to BVDU -mediated cytotoxicity, other less common mechanisms may play an important role as well. For example, the antirecombinogenic and co -mutagenic properties of BVDU, as observed when co -administrated with certain chemotherapeutic agents, may possibly enhance GCV-induced DNA damage through its co -mutagenic effects and inhibit recombinogenic events associated with repair processes occurring after GCV-mediated DNA damage. 43 Whether such mechanisms play a role in the interaction of GCV and BVDU should be addressed in future studies.
One of the main reasons for the very limited efficacy of gene therapy is the low transduction rate of current gene vectors in vivo. Thus, the bystander effect is regarded as an important factor in several treatment strategies. 28,30 ± 33 For this reason, there have been attempts to exploit the bystander effect for the treatment of tumors in vivo, thereby bypassing the current limitations of available vector systems. 44 The data presented in this paper indicate that BVDU not only can enhance GCV-mediated cytotoxicity on responding HSVtk ±expressing cells but also on HSV-tk À bystander cells. There is ample evidence that the bystander effect is mediated by gap junctional intercellular communication enabling the exchange of nucleotides and nucleotide analogues between cells.
28,30 ± 33 BVDU is a nucleotide analog with a molecular mass of <1 kDa and, thus, should readily be transferred between cells in a manner demonstrated for other nucleotides and their analogues. A bystander effect, in conjunction with BVDU treatment, has also been suggested by other studies, although pyrimidine nucleoside analogues ( e.g., BVDU ) appear to exert a less potent bystander effect than purine nucleoside analogues (e.g., GCV ). 45, 46 Our observations warrant further investigations in vivo. In preliminary experiments examining a subcutaneous 9L STK tumor model in Balb / c and NMRI nude mice, BVDU did not lead to significant tumor growth reduction (data not shown ). Although BVDU has recently been demonstrated to exert antitumor effects in herpes virus thymidine kinase ±express-ing tumors in vivo, it is interesting that GCV appears to be the more potent drug in vivo. 45, 47 Moreover, BVDU did not inhibit growth of varicella zoster virus thymidine kinase expressing 9L gliosarcomas in syngeneic rats. 47 This suggests inconsistent effects of BVDU on the in vivo growth of tumors. With more data being available about the in vivo effects of BVDU, it will become easier to define appropriate systems for the evaluation of combined antitumor effects of GCV and BVDU in vivo.
